Summary
The product HCG 5000 IU, manufactured by Biogenix Pharma, underwent independent testing to verify its potency. The sample, with no specified batch number, was submitted by BiogenixPharma and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of HCG, with a concentration of 4932 IU, which is 1.36% below the labeled claim of 5000 IU.
The testing process began on 11 August 2024, with the sample received on 22 August 2024, and analysis completed on 23 August 2024. While the results confirm near-accurate dosing, scrutiny of reseller-submitted samples is essential to ensure reliability. Resellers may select specific batches that meet high-quality standards, raising questions about product consistency across the broader market. Independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Biogenix Pharma
- Product Name: HCG 5000 IU
- Active Ingredient: Human Chorionic Gonadotropin (HCG)
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #47813
- Testing Ordered: 11 August 2024
- Sample Received: 22 August 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Optitropin.EU (Reseller)
- Analysis Paid For By: Optitropin.EU
Testing Results
- Specification: 5000 IU (as stated on the label)
- Measured Concentration: 4932 IU
- Accuracy: 98.64% (1.36% below the label claim)
- Variance: 1.36
Verification Details
- Verification URL: https://janoshik.com/tests/47813_NX5MKKLJRWD6
Evaluation of Reseller-Submitted Testing
This analysis highlights the near-accurate dosing of the tested product but warrants careful evaluation due to its submission and funding by the reseller BiogenixPharma. Resellers often select optimal batches for testing, which may not fully represent the consistency of products available to consumers. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple batches.
Conclusion
The analysis confirms that HCG 5000 IU is slightly underdosed, with a measured concentration of 4932 IU. This result reflects strong quality control for this sample but underscores the importance of additional testing to ensure consistent dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding peptide products.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
